Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model]
RNA-seq (gene expression) · mouse · 19 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 19 samples: 19 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE248154_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1041838 and SRA study SRP472626. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 19 sample titles: 19 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7906491 4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#1)
- GSM7906492 4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#2)
- GSM7906493 4NQO-induced oral cancer models with treatment of anti-CD40 agonist (#3)
- GSM7906494 4NQO-induced oral cancer models with treatment of vehicle control (#1)
- GSM7906495 4NQO-induced oral cancer models with treatment of vehicle control (#2)
- GSM7906496 4NQO-induced oral cancer models with treatment of vehicle control (#3)
- GSM7906497 4NQO-induced oral cancer models with treatment of vehicle control (#4)
- GSM7906498 4NQO-induced oral cancer models with treatment of anti-PD1 (#1)
- GSM7906499 4NQO-induced oral cancer models with treatment of anti-PD1 (#2)
- GSM7906500 4NQO-induced oral cancer models with treatment of anti-PD1 (#3)
- GSM7906501 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#1)
- GSM7906502 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#2)
- GSM7906503 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#3)
- GSM7906504 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#4)
- GSM7906505 4NQO-induced oral cancer models with treatment of anti-PD1 + regorafenib (#5)
- GSM7906506 4NQO-induced oral cancer models with treatment of regorafenib (#1)
- GSM7906507 4NQO-induced oral cancer models with treatment of regorafenib (#2)
- GSM7906508 4NQO-induced oral cancer models with treatment of regorafenib (#3)
- GSM7906509 4NQO-induced oral cancer models with treatment of regorafenib (#4)
- GSE248155 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma 31 samples shares anti-cd40, anti-pd1, regorafenib, squamous, agonist, head, neck
- GSE248153 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [HNSCC_model] 12 samples shares anti-cd40, anti-pd1, regorafenib, squamous, agonist, head, neck
- GSE207504 Single-cell Sequencing Analysis Identifies Intratumoral Immune Cell Population in Head and Neck Squamous Cell Carcinoma from 4NQO-induced Mice upon JQ1 treatment 2 samples shares 4nqo, squamous, head, neck
- GSE311831 Pertussis toxin-induced lymphocytosis enhances anti-tumor immune environments and improves the anti-PD1 treatment response in a squamous cell carcinoma model. 24 samples shares anti-pd1, squamous
- GSE232557 Effects of anti-CD40 agonist and Cabozantinib on the immune microenvironment of mouse hepatocellular carcinoma 1 samples shares anti-cd40, agonist
- GSE285902 IL-15 complex enhances agonistic anti-CD40 + anti-PDL1 by correcting the T-bet to Tox ratio in CD8+ T cells infiltrating pancreatic ductal adenocarcinoma 9 samples shares anti-cd40, agonist
- GSE272309 Investigate the role of B cell in response to anti-PD1 + anti-CTLA in hepatocellular carcinoma 21 samples shares anti-pd1
- GSE289771 Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy 20 samples shares anti-pd1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.